Twist Bioscience Corporation Q4 2025 Earnings Recap

TWST Q4 2025 November 15, 2025

Twist Bioscience achieved a record revenue of $99 million in Q4 2025, marking a 17% year-over-year increase and contributing to a 20% annual growth, driven by strong demand for its Synbio and NGS product offerings.

Earnings Per Share Beat

$-0.45 vs $-0.50 est.

+10.0% surprise

Revenue Beat

99009000 vs 97400000 est.

+1.7% surprise

Market Reaction

1-Day +0.0%

5-Day -2.98%

30-Day +22.07%

Key Takeaways

Full year revenue reached $376.6 million, with a gross margin improvement to 50.7%, up from 42.6% in fiscal 2024.
Revenues from Synbio increased by 17% to $39.5 million, fueled by demand for the Express portfolio and growth in AI-enabled drug discovery initiatives.
Next Generation Sequencing (NGS) revenue grew 16% to $53 million, supported by commercial success in diagnostic clinical assays.
The company plans to introduce new products and services, anticipating continued revenue growth and aiming for adjusted EBITDA breakeven by the end of fiscal 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TWST on AllInvestView.

Next Q1 2026